Content about Carbidopa

December 20, 2012
Mylan, Orion settle Parkinson's disease drug case

Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday

PITTSBURGH — Generic drug maker Mylan has settled with Orion over a drug used to treat Parkinson's disease, Mylan said Thursday.

The company said it reached a settlement with Orion to resolve patent litigation concerning a generic version of Orion's drug Comtan (entacapone) tablets in the 200-mg strength. The drug is used with levodopa-carbidopa therapy to treat Parkinson's patients who experience signs and symptoms of end-of-dose "wearing off."

November 27, 2012
Wockhardt receives three FDA approvals

Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

SILVER SPRING, Md. — Indian generic drug maker Wockhardt received three new drug approvals from the Food and Drug Administration, agency records show.

February 23, 2012
FDA accepts NDA filing for Impax's Parkinson's disease treatment

The Food and Drug Administration has accepted a new drug application for the treatment of idiopathic Parkinson’s disease.

HAYWARD, Calif. — The Food and Drug Administration has accepted a new drug application for the treatment of idiopathic Parkinson’s disease.

Impax Pharmaceuticals, the branded products division of Impax Labs, said it filed its NDA for the investigational drug IPX066, an extended-release capsule formulation of carbidopa-levodopa, for review in December 2011. IPX066 has been licensed to GlaxoSmithKline for countries outside the United States and Taiwan for development and marketing.

August 15, 2011
Study: Investigational GSK, Impax drug reduces Parkinson's symptoms

Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking standard therapies, according to results of a late-stage clinical trial.

HAYWARD, Calif. — Patients taking an experimental treatment for Parkinson's disease experienced greater reduction in symptoms than those taking a drug already on the market, according to results of a late-stage clinical trial.

July 26, 2011
Impax enrolls patients into late-stage trial for Parkinson's treatment

The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

HAYWARD, Calif. — The branded drugs division of Impax Labs has finished enrolling patients in a late-stage trial of a drug for Parkinson’s disease.

Impax Pharmaceuticals said Tuesday that it had enrolled patients in ASCEND-PD, a phase-3 trial of IPX066 that will compare the drug with carbidopa-levodopa and entacapone in patients with advanced Parkinson’s. IPX066 is an extended-release formulation of carbidopa-levodopa in capsule form.

June 9, 2011
Abbott: LCIG may improve Parkinson's disease symptoms among patients

Patients with Parkinson’s disease treated with an investigational drug made by Abbott saw a decrease in the amount of time their symptoms resurfaced, while the time in which their symptoms stayed under control increased, according to results of a late-stage clinical trial that Abbott announced Thursday.

ABBOTT PARK, Ill. — Patients with Parkinson’s disease treated with an investigational drug made by Abbott saw a decrease in the amount of time their symptoms resurfaced, while the time in which their symptoms stayed under control increased, according to results of a late-stage clinical trial that Abbott announced Thursday.

April 1, 2011
Impax says Parkinson's disease treatment is safe, effective

An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.

HAYWARD, Calif. — An investigational drug for Parkinson’s disease was safe and effective, according to results of a late-stage clinical trial scheduled for presentation next week.

Impax Pharmaceuticals, the branded products division of Impax Labs, said it would present data from a phase-3 trial of extended-release IPX066 (carbidopa-levodopa) at the American Academy of Neurology Conference’s annual meeting in Hawaii, which takes place from April 9 through April 16.

The company also said there were no unexpected serious side effects observed in patients.

March 30, 2010
FDA: Stalevo may increase male patients' risk of cancer

Data from a long-term clinical trial may indicate a possible cancer risk in men taking...